Important notices / appeals / warnings

Silimed: silIcone implants suspended temporarely
Read the communication of SWISSMEDIC and the article from Figaro.

(ALCL) - Anaplastic large cell lymphoma related to breast implants

Two weeks ago (mid-March 2015) the French Ministry of Health announced a connection between breast implants and the occurrence of ALCL. ALCL is a very rare form of cancer. Although this risk must be taken into account, there are no scientific grounds to alarm the general public and generate unnecessary panic. Breast implantation is still regarded as a safe procedure.

Recommendations for patients:
° monitor implants regularly - contact your doctor immediately if you notice any change
° regular mammography screenings
° regular MRI of implants in order to exclude ruptures (3 years after the initial procedure, then every 2 years thereafter)

Read the full statement of position by SWISS PLASTIC SURGERY.

Better monitoring of implants
Switzerland is aiming to come into line with the European Union (EU) and improve the safety of medical products. To avoid further scandals such as the PIP breast implants, the Federal Council has decided to amend the ordinance governing these implants.

PIP implants
As agreed in consultation with SWISS PLASTIC SURGERY, Swissmedic continues to advise against automatic explantation of PIP implants.

Call to all women fitted with PIP implants

PIP implants were withdrawn from the market in the spring of 2010. Patients who were fitted with PIP implants are asked to contact their physician or get in touch with the office of SWISS PLASTIC SURGERY or SWISSMEDIC:  +41 21 963 21 39 - -

As things stand at present, there is no need to remove intact PIP implants. However, it is advisable to have yourself examined by a specialist every 6 months.

Important: So far there has been no proof of an increase in breast cancer in women with PIP implants. Even in cases where the implant proved defective, no carcinogenic substances have been found.

New studies and treatments for breast cancer - costs reimbursed.

From 1 January 2015, the compulsory health insurance reimburses the cost of genetic examinations of breast cancer tissue. These examinations help with the decision on the type and necessity of chemotherapy.

In addition, the basic insurance now also reimburses breast cancer patients for partial breast reconstruction. Formerly it only bore the costs if the entire breast had to be reconstructed. The compulsory health insurance now also bears the costs of reducing the healthy breast.